

Technical recommendations for liquid chromatography-mass spectrometry analysis of oxylipins.

Nils Helge Schebb^{*,#1}, Nadja Kampschulte¹, Gerhard Hagn², Kathrin Plitzko¹, Sven W. Meckelmann³, Soumita Ghosh⁴, Robin Joshi⁴, Julia Kuligowski⁵, Dajana Vuckovic⁶, Marina T. Botana^{2,7}, Ángel Sánchez-Illana⁸, Fereshteh Zandkarimi⁹, Aditi Das¹⁰, Jun Yang¹¹, Louis Schmidt¹², Antonio Checa², Helen M. Roche^{13,14}, Aaron M. Armando¹⁵, Matthew L. Edin¹⁶, Fred B. Lih¹⁶, Juan J. Aristizabal-Henao¹⁷, Sayuri Miyamoto¹⁸, Francesca Giuffrida¹⁹, Arie Moussaieff²⁰, Rosário Domingues²¹, Michael Rothe²², Christine Hinz²³, Ujjalkumar Subhash Das⁴, Katharina M. Rund¹, Ameer Y. Taha²⁴, Robert K. Hofstetter²⁵, Markus Werner²⁵, Oliver Werz²⁵, Astrid Kahnt²⁶, Justine Bertrand-Michel²⁷, Pauline Le Faouder²⁷, Robert Gurke^{28,29,30}, Dominique Thomas^{28,29,30}, Federico Torta^{31,32}, Ivana Milic³³, Irundika H. K. Dias³⁴, Corinne M. Spickett³³, Denise Biagini³⁵, Tommaso Lomonaco³⁵, Helena Idborg³⁶, Jun-Yan Liu³⁷, Maria Fedorova³⁸, David A. Ford³⁹, Anne Barden⁴⁰, Trevor A Mori⁴⁰, Paul D. Kennedy⁴¹, Kirk Maxey⁴¹, Julijana Ivanisevic⁴², Hector Gallart-Ayala⁴², Cécile Gladine⁴³, Markus Wenk⁴⁴, Jean-Marie Galano⁴⁵, Thierry Durand⁴⁵, Ken D. Stark⁴⁶, Coral Barbas⁴⁷, Ulrike Garscha¹², Stacy L. Gelhaus^{48,49}, Uta Ceglarek⁵⁰, Nicolas Flamand⁵¹, Julian L. Griffin⁵², Robert Ahrends⁵³, Makoto Arita⁵⁴, Darryl C. Zeldin¹⁶, Francisco J. Schopfer⁴⁹, Oswald Quehenberger¹⁵, Randall Julian⁵⁵, Anna Nicolaou⁵⁶, Ian A. Blair⁵⁷, Michael P. Murphy⁵⁸, Bruce D. Hammock¹¹, Bruce Freeman⁴⁹, Gerhard Liebisch⁵⁹, Charles N. Serhan⁶⁰, Harald C. Köfeler⁶¹, Per-Johan Jakobsson³⁶, Dieter Steinhilber²⁶, Michael H. Gelb⁶², Michal Holčápek⁶³, Ruth Andrew⁶⁴, Martin Giera⁶⁵, Garret A. FitzGerald⁴, Robert C. Murphy⁶⁶, John W. Newman⁶⁷, Edward A. Dennis¹⁵, Kim Ekroos⁶⁸, Ginger L. Milne⁶⁹, Miguel A. Gijón⁴¹, Hubert W. Vesper⁷⁰, Craig E. Wheelock^{2,71}, Valerie B. O'Donnell⁷²

* E-mail: nils@schebb-web.de

International Lipidomics Society Oxylipin Interest Group Member

Abstract

Several oxylipins are potent lipid mediators regulating diverse aspects of health and disease, whose quantitative analysis by liquid chromatography mass spectrometry (LC-MS) represents significant technical challenges. In this issue of *Science Signaling*, Schebb et al. report detailed technical recommendations developed by the lipidomics community, that provide guidance for good practice when quantifying oxylipins by LC-MS.

Lipid signaling mediators are essential players in health and disease, participating in diverse cellular processes related to inflammation, immunity, development, and homeostasis. A major category of lipid mediators, comprising large families of structurally related fatty acyls are oxylipins, which include eicosanoids such as prostaglandins (PG), thromboxanes (TX), leukotrienes (LT) and epoxyeicosatrienoic acids (EETs) all derived from arachidonic acid. Other oxylipins derive from shorter or longer chain

polyunsaturated fatty acids (PUFA), such as octadecanoids or docosanoids, including specialized pro-resolving mediators (SPM). While most are generated by enzymes such as lipoxygenases (LOX), cyclooxygenases (COX) and cytochrome P450 monooxygenases (CYP), they can also be formed non-enzymatically by autoxidation. The relevance of oxylipins to human disease is undisputed. For example, well-known drugs target the prostaglandin pathway to modulate inflammatory diseases, including non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac. Alongside this, aspirin, which blocks thromboxane biosynthesis when used at low doses, is the most widely prescribed drug globally, with a major role in the secondary prevention of cardiovascular diseases, and emerging potential in reducing cancer incidence (1).

Eicosanoids derived from arachidonic acid were first discovered in the 1930s by von Euler (2). This was followed by structural characterization of PGs and TXs in the second half of the 20th century leading to the awarding of the Nobel Prize to Bergström and Samuelsson in 1982 (3), along with Vane for discovery of aspirin's mechanism of action (4). In more recent decades, additional families were found, and key mechanisms of oxylipin signaling, metabolism and excretion in urine were revealed in numerous biological and pathophysiological contexts. Following their initial discovery, they were often named based on their cellular source, for example, prostaglandins were first identified in seminal vesicles. Alternatively, they were named based on a combination of source and chemical structure, for example with LT made by white blood cells and carrying a triene motif. While they are often described as lipid mediators or autacoids that are secreted by cells to act on receptors locally, the biological functions of many oxylipins are still to be established. Only some, for example, PGs and LTs, have G protein-coupled receptors that are formally validated by the International Union of Pharmacology (IUPHAR). In the LIPID MAPS classification (5), oxylipins are listed under Fatty Acyls, within the main classes, octadecanoids (C₁₈), eicosanoids (C₂₀), and docosanoids (C₂₂).

As more and more oxylipins continue to be discovered and characterized, and interest in their bioactivity and pre-clinical measurement explodes, it becomes essential for researchers to have access to robust analytical methods that allow their sensitive and selective quantification. It is also important that these methods account for the complexity of oxylipin analysis, while leveraging the high capability of newer generation liquid chromatography (LC) tandem mass spectrometry (MS/MS). Over the past 20 years, oxylipin analysis has significantly advanced. Indeed, today's state-of-the-art targeted LC-MS/MS assays can routinely quantify over 100 individual molecular species in small amounts of biofluids or tissue extracts, down to low- or sub-pg on-column in a single analytical run (see supplementary text for references). While this is already transforming research into these lipids, there remains a major need to support researchers new to this field who wish to establish these assays. Oxylipins present unique analytical challenges that include low abundance, rapid metabolism to conjugated or chain-shortened forms, presence of a large number of closely eluting isomers, and similar fragmentation patterns, especially when generated non-enzymatically. Considering this, quantitative analysis of oxylipin families is technically specialist, requiring both chromatography and MS/MS, as well as the availability of authentic and stable isotope labelled synthetic analytical standards.

The quantification of oxylipins requires accuracy and precision as well as correct identification and reporting. Given that some are present at extremely low endogenous concentrations, it is important to ensure that their measurements adhere to best practices. More broadly, in the wider field of lipidomics, in response to challenges with data reporting and reproducibility, guidelines have been recently developed, including a Minimal Reporting Checklist (6, 7). More information on these specific issues, with references, is provided in the supplement to this Focus article. Following from that work, but specifically supporting researchers interested in performing oxylipin analysis, community recommendations have been developed and are presented here. These summarize the key aspects to be considered when establishing and routinely running a targeted LC-MS/MS method for oxylipin quantitation in research settings and describes which parameters should be reported in publications. Criteria for routine quantitation are proposed, along with parameters to be reported when establishing new methods. Additional methods such as high-resolution accurate mass analysis, data-dependent and data-independent fragmentation, ion mobility, or MS imaging are not covered, but in general the same overall criteria for performance described herein should apply. The recommendations also contain an extended and fully referenced introduction providing a more comprehensive history of the discovery of oxylipins, and their MS/MS analysis, than could be included here due to space limitations.

For targeted analysis in a clinical setting, numerous guidelines for bioanalytical methods already exist, for example from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the Food and Drug Administration (FDA) and the Clinical & Laboratory Standards Institute (CLSI) (8-10). These describe requirements for laboratory methods used in patient care, clinical trials and diagnostics. However, they do not appropriately address the needs and limitations typically observed in basic research settings aimed to increase the understanding the underlying mechanisms of diseases and biological processes. Examples for these limitations include the restricted availability of standards and reference materials, diversity in sample matrix type and sample origin, as well as the lack of analyte-free matrices. Furthermore, they do not provide specific details related to oxylipins. Addressing this, the new recommendations provide technical advice for oxylipin analysis in laboratories reflecting current state-of-the-art practices in discovery research. Where analysts are using oxylipin assays measures for clinical or diagnostic purposes, then the above-mentioned guidelines need to be applied, in addition.

These community recommendations for laboratory assays for oxylipins were initiated by a working group initially established as an International Lipidomics Society (ILS) Interest Group (https://lipidomicssociety.org/interest_groups/oxylipin-analysis/). Following open advertisement to the biomedical community where interested researchers were invited to attend, two webinars were held to discuss basic analytical principles which should be included (87 attendees). Following feedback *via* an online form and emails, a draft was generated, then circulated to webinar attendees and others for input. After revision, an agreed-upon version was finalized and is presented as a Supplement to this Focus article. These recommendations are fully aligned with the ILS Minimal Reporting Checklist which should be used alongside this for data reporting (6).

¹Chair of Food Chemistry, School of Mathematics and Natural Sciences, University of Wuppertal, Germany. ²Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ³Applied Analytical Chemistry, University of Duisburg-Essen, Essen, Germany. ⁴Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁵Neonatal Research Group, Health Research Institute La Fe (IIS La Fe), Valencia, Spain. ⁶Department of Chemistry and Biochemistry, Concordia University, Montreal, Canada. ⁷School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand. ⁸Department of Analytical Chemistry, University of Valencia, Burjassot, Spain. ⁹Mass Spectrometry Core Facility, Department of Chemistry, Columbia University, New York, NY, USA. ¹⁰School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA. ¹¹Department of Entomology, University of California, Davis, CA, USA. ¹²Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Germany. ¹³Nutrigenomics Research Group, UCD Conway Institute, School of Public Health, Physiotherapy and Sports Science, University College Dublin, Ireland. ¹⁴Institute for Global Food Security, Queen's University Belfast, Northern-Ireland. ¹⁵Department of Pharmacology and Department of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA, USA. ¹⁶Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA. ¹⁷BPG Bio, Framingham, MA, USA. ¹⁸Department of Biochemistry, Institute of Chemistry, University of São Paulo, Brazil. ¹⁹Nestlé Institute of Food Safety and Analytical Sciences, Société des Produits Nestlé, Lausanne, Switzerland. ²⁰Faculty of Medicine, Hebrew University of Jerusalem, Israel. ²¹Department of Chemistry, University of Aveiro, Portugal. ²²Lipidomix GmbH, Berlin, Germany. ²³Shimadzu UK Ltd, Milton Keynes, UK. ²⁴Department Food Science and Technology, University of California, Davis, CA, USA. ²⁵Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University, Jena, Germany. ²⁶Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany. ²⁷MetaboHUB-MetaToul, I2MC, Université de Toulouse, Inserm, Université Toulouse III – Paul Sabatier (UPS), France. ²⁸Faculty of Medicine, Institute of Clinical Pharmacology, Goethe University Frankfurt, Frankfurt am Main, Germany. ²⁹Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany. ³⁰Fraunhofer Cluster of Excellence of Immune Mediate Diseases CIMD, Frankfurt am Main, Germany. ³¹Signature Research Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore (NUS) Medical School, Singapore. ³²Singapore Lipidomics Incubator, Life Sciences Institute and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ³³School of Biosciences & Aston Institute for Membrane Excellence, Aston University, Aston Triangle, Birmingham, UK. ³⁴Aston Medical School, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, UK. ³⁵Department of Chemistry and Industrial Chemistry, University of Pisa, Italy. ³⁶Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden. ³⁷Center for Novel Target & Therapeutic Intervention, College of Pharmacy, Chongqing Medical University, Chongqing, P. R. China. ³⁸Center of Membrane Biochemistry and Lipid Research, University Hospital and Faculty of Medicine Carl Gustav Carus of TU Dresden, Dresden, Germany. ³⁹Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, MO, USA. ⁴⁰Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia. ⁴¹Cayman Chemical Company, Ann Arbor, MI, USA. ⁴²Metabolomics and Lipidomics Platform, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland. ⁴³Université Clermont Auvergne, INRAE, UNH, Unité de Nutrition Humaine, CRNH Auvergne, Clermont-Ferrand, France. ⁴⁴College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar. ⁴⁵Institut des Biomolécules Max Mousseron (IBMM), Pôle Chimie Balard Recherche, CNRS, Université de Montpellier, ENSCN, France. ⁴⁶Department of Kinesiology and Health Sciences, University of Waterloo, Canada. ⁴⁷Centre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, CEU San Pablo University, Madrid, Spain. ⁴⁸Health Sciences Mass Spectrometry Core, University of Pittsburgh, PA, USA. ⁴⁹Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA. ⁵⁰Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig Medical Center, Germany. ⁵¹Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Département de médecine, Faculté de médecine, Université Laval, Québec City, Canada. ⁵²The Rowett Institute, School of Medicine, Medical Science and Nutrition, University of Aberdeen, UK. ⁵³Department of Analytical Chemistry, University of Vienna, Austria. ⁵⁴RIKEN Center for Integrative Medical Sciences (IMS), Yokohama, Kanagawa, Japan. ⁵⁵indigo BioAutomation, Carmel, IN, USA. ⁵⁶Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology Medicine and Health, University of Manchester, UK. ⁵⁷Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. ⁵⁸Medical Research Council Mitochondrial Biology Unit and Department of Medicine, University of Cambridge, UK. ⁵⁹Institute of Clinical Chemistry and Laboratory Medicine, Institute University Hospital Regensburg, Germany. ⁶⁰Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Hale Building for Transformative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ⁶¹Core Facility Mass Spectrometry, ZMF, Medical University of Graz, Austria. ⁶²Department of Chemistry, University of Washington, Seattle, WA, USA. ⁶³Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic. ⁶⁴Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, UK. ⁶⁵Leiden University Medical Center, The Netherlands. ⁶⁶Department of Pharmacology, University of Colorado Denver, Denver, CO, USA. ⁶⁷USDA ARS Western Human Nutrition Research Center and Department of Nutrition, University of California, Davis, CA, USA. ⁶⁸Lipidomics Consulting Ltd., Esbo, Finland. ⁶⁹Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, USA. ⁷⁰Centers for Disease Control and Prevention, Atlanta, GA, USA. ⁷¹Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden. ⁷²School of Medicine, Cardiff University, Heath Park, Cardiff, UK.

Competing financial interests

VBD is a consultant for Metasight. BDH is a founder of EicOsis Human Health with a potential pharmaceutical in clinical trials whose action depends on altering the profile of inflammatory lipids. MG is a cofounder of the company Enfanos, LLC. BF acknowledges a financial interest in Creegh Pharmaceuticals Inc.. EAD is a cofounder of LipoNexus, Inc..

Funding

We gratefully acknowledge the following funding sources: LIPID MAPS (MRC: MR/Y000064/1), US National Institutes of Health (R01 GM125944, FJS; R01 HL132550, P01 HL103455 and R33 HL157069, BF; S10 OD23402 and S10 OD032141, SLG; U54 NS127758, BDH; R35 GM139641, EAD), US National Institute of Environmental Health Sciences (Z01 ES025034, DZ; R35 ES030443-01 and P42 ES004699, BDH), US Department of Agriculture (2032-51530-025-00D, JWN), Medical Research Council (MR/Y000064/1, VOD; MC_UU_00028/4, MPM; BB/W018322/1, RD), European Union (JDC2022-049354-I, ASI; ERC Adv grant No. 101095860, MH; CA19105, MF and RD; 847419, CS), Wellcome Trust (220257/Z/20/Z, MPM), German Research Foundation (SCHE 1801, NHS; FE 1236/5-1 and FE 1236/8-1, MF; SFB 1039/Z01, RG and DT), German Federal Ministry of Education and Research (BMBF 031L0315A, DEEP_HCC and 01EJ2205A and FERROPath, MF), São Paulo Research Foundation (FAPESP #2013/07937-8, SM), Carlos III Health Institute (CP21II/00003, JK), Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03777, NF), The Portuguese Centre for the Environment and Marine Studies CESAM (UIDB/50017/2020 + UIDP/50017/2020 + LA/P/0094/2020, RD), Alzheimer's Association (AARGD-22-926459, ID) and the Spanish Ministerio de Ciencia e Innovación (10.13039/501100011033, ASI).

1. E. Ricciotti, G. A. FitzGerald, Aspirin in the Prevention of Cardiovascular Disease and Cancer. *Annu Rev Med* **72**, 473-495 (2021); published online EpubJan 27 (10.1146/annurev-med-051019-102940).
2. U. S. von Euler, On the specific vasodilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). *J. Physiol. (Lond.)* **88**, 213 (1936).
3. S. Bergstroem, H. Danielsson, B. Samuelsson, The Enzymatic Formation of Prostaglandin E2 from Arachidonic Acid Prostaglandins and Related Factors 32. *Biochim Biophys Acta* **90**, 207-210 (1964); published online EpubJul 15 (10.1016/0304-4165(64)90145-x).
4. J. R. Vane, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nat New Biol* **231**, 232-235 (1971); published online EpubJun 23 (10.1038/newbio231232a0).
5. E. Fahy, S. Subramaniam, H. A. Brown, C. K. Glass, A. H. Merrill, Jr., R. C. Murphy, C. R. Raetz, D. W. Russell, Y. Seyama, W. Shaw, T. Shimizu, F. Spener, G. van Meer, M. S. VanNieuwenhze, S. H. White, J. L. Witztum, E. A. Dennis, A comprehensive classification system for lipids. *J Lipid Res* **46**, 839-861 (2005); published online EpubMay (10.1194/jlr.E400004-JLR200).
6. D. Kopczynski, C. S. Ejsing, J. G. McDonald, T. Bamba, E. S. Baker, J. Bertrand-Michel, B. Brugger, C. Coman, S. R. Ellis, T. J. Garrett, W. J. Griffiths, X. L. Guan, X. Han, M. Horing, M. Holcapek, N. Hoffmann, K. Huynh, R. Lehmann, J. W. Jones, R. Kaddurah-Daouk, H. C. Kofeler, P. J. Meikle, T. O. Metz, V. B. O'Donnell, D. Saigusa, D. Schwudke, A. Shevchenko, F. Torta, J. A. Vizcaino, R. Welti, M. R. Wenk, D. Wolrab, Y. Xia, K. Ekroos, R. Ahrends, G. Liebisch, The Lipidomics Reporting Checklist A framework for transparency of lipidomic experiments and repurposing resource data. *J Lipid Res*, 100621 (2024); published online EpubAug 14 (10.1016/j.jlr.2024.100621).
7. G. Liebisch, K. Ekroos, M. Hermansson, C. S. Ejsing, Reporting of lipidomics data should be standardized. *Biochim Biophys Acta Mol Cell Biol Lipids* **1862**, 747-751 (2017); published online EpubAug (10.1016/j.bbalip.2017.02.013).
8. *International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH): ICH guideline M10 on bioanalytical method validation and study sample analysis* (2022).
9. *Bioanalytical Method Validation Guidance for Industry, FDA/CDER/CVM 2001* (2018).
10. K. L. Lynch, CLSI C62-A: A New Standard for Clinical Mass Spectrometry. *Clin Chem* **62**, 24-29 (2016); published online EpubJan (10.1373/clinchem.2015.238626).